Patents by Inventor Kimberly Vanover

Kimberly Vanover has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating post-traumatic stress disorder
    Patent number: 12624036
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: May 12, 2026
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Robert Davis, Kimberly Vanover
  • Method of treating agitation, aggressive behavior, and impulse control disorder
    Patent number: 12624037
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: May 12, 2026
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Robert Davis, Kimberly Vanover
  • Deuterated organic compounds and uses thereof
    Patent number: 12606523
    Abstract: Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.
    Type: Grant
    Filed: July 3, 2024
    Date of Patent: April 21, 2026
    Assignee: ENGRAIL THERAPEUTICS, INC.
    Inventors: Krishna Vadodaria, Kimberly Vanover, Jordi Serrats, Vikram Sudarsan, David Garvey
  • DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF
    Publication number: 20260098011
    Abstract: Provided are compounds of Formula I and Formula II, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I and Formula II are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.
    Type: Application
    Filed: June 11, 2025
    Publication date: April 9, 2026
    Inventors: Krishna VADODARIA, Kimberly VANOVER, Vikram SUDARSAN, David GARVEY
  • Compounds and methods
    Patent number: 12565499
    Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.
    Type: Grant
    Filed: March 11, 2024
    Date of Patent: March 3, 2026
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Robert Davis, Kimberly Vanover, Lawrence Wennogle
  • ORGANIC COMPOUND
    Publication number: 20250382310
    Abstract: The invention relates to a particular substituted heterocycle fused gamma-carboline, the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.
    Type: Application
    Filed: September 2, 2025
    Publication date: December 18, 2025
    Inventors: Peng LI, Robert E DAVIS, Kimberly Vanover
  • NOVEL METHODS
    Publication number: 20250360140
    Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
    Type: Application
    Filed: August 8, 2025
    Publication date: November 27, 2025
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Kimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
  • Organic compounds
    Patent number: 12440489
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: November 6, 2023
    Date of Patent: October 14, 2025
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei Yao, Peng Li, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • METHODS OF TREATING NEUROPATHIC PAIN
    Publication number: 20250312340
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, for use in methods for the treatment of neuropathic pain.
    Type: Application
    Filed: June 16, 2025
    Publication date: October 9, 2025
    Inventors: Robert DAVIS, Gretchen SNYDER, Kimberly VANOVER
  • Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
    Patent number: 12410195
    Abstract: The invention relates to pharmaceutical compositions comprising the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.
    Type: Grant
    Filed: June 12, 2024
    Date of Patent: September 9, 2025
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Robert E Davis, Kimberly Vanover
  • Deuterated organic compounds and uses thereof
    Patent number: 12365650
    Abstract: Provided are compounds of Formula I and Formula II, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I and Formula II are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.
    Type: Grant
    Filed: July 2, 2024
    Date of Patent: July 22, 2025
    Assignee: ENGRAIL THERAPEUTICS, INC.
    Inventors: Krishna Vadodaria, Kimberly Vanover, Vikram Sudarsan, David Garvey
  • Organic compounds
    Patent number: 12325726
    Abstract: The invention relates to particular prodrugs and analogs of (3?,5?)-3-hydroxy-21-(1H-imidazol-1-yl)-3-methoxymethyl)-pregnan-20-one, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as sedatives, hypnotics, anxiolytics, and/or anesthetics, and methods for treatment of depression, anxiety, insomnia, epilepsy, and other central nervous system disorders, as well as to combinations with other agents.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: June 10, 2025
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Kimberly Vanover, Peng Li, Robert Davis, Yupu Qiao
  • DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF
    Publication number: 20250145568
    Abstract: Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.
    Type: Application
    Filed: July 2, 2024
    Publication date: May 8, 2025
    Inventors: Krishna VADODARIA, Kimberly VANOVER, Vikram SUDARSAN, David GARVEY
  • DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF
    Publication number: 20250091990
    Abstract: Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.
    Type: Application
    Filed: January 3, 2023
    Publication date: March 20, 2025
    Inventors: Krishna VADODARIA, Kimberly VANOVER, Jordi SERRATS, Vikram SUDARSAN, David GARVEY
  • Organic compounds
    Patent number: 12195463
    Abstract: The invention relates to a particular enantiomer of a substituted heterocycle fused gamma-carboline, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, and pathways involving the dopamine D1 and D2 receptor signaling system.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: January 14, 2025
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Kimberly Vanover, Robert Davis
  • DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF
    Publication number: 20250011280
    Abstract: Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.
    Type: Application
    Filed: July 3, 2024
    Publication date: January 9, 2025
    Inventors: Krishna VADODARIA, Kimberly VANOVER, Jordi SERRATS, Vikram SUDARSAN, David GARVEY
  • DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF
    Publication number: 20250011279
    Abstract: Provided are compounds of Formula I and Formula II, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I and Formula II are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.
    Type: Application
    Filed: July 2, 2024
    Publication date: January 9, 2025
    Inventors: Krishna VADODARIA, Kimberly VANOVER, Vikram SUDARSAN, David GARVEY
  • Pharmaceutical compositions comprising heterocycle fused gamma carboline prodrugs
    Patent number: 12173004
    Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: August 17, 2023
    Date of Patent: December 24, 2024
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • NOVEL METHODS
    Publication number: 20240374586
    Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.
    Type: Application
    Filed: July 19, 2024
    Publication date: November 14, 2024
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER
  • Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
    Patent number: 12122792
    Abstract: The invention relates to pharmaceutical compositions comprising the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.
    Type: Grant
    Filed: August 31, 2023
    Date of Patent: October 22, 2024
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Robert E Davis, Kimberly Vanover